Can rimonabant (Acomplia) be used to treat obesity?

Updated: Feb 20, 2019
  • Author: Steven M Schwarz, MD, FAAP, FACN, AGAF; Chief Editor: Jatinder Bhatia, MBBS, FAAP  more...
  • Print
Answer

Rimonabant (Acomplia), an anorectic agent with specific cannabinoid receptor inhibition, was approved in several European countries in 2006; however, it was unanimously denied approval by the FDA's Endocrinologic and Metabolic Drugs Advisory Committee in June 2007. The FDA committee said that more detailed long-term safety information with larger patient numbers was needed with regard to neurologic and psychiatric side effects that have been associated with the drug, including seizures, depression, anxiety, insomnia, aggressiveness, and suicidal thoughts. Nonetheless, rimonabant is approved for sale in 42 countries and is marketed for obesity with associated cardiovascular risk in 20 countries.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!